Trials / Completed
CompletedNCT00111020
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,567 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2007-06-01
- Completion
- 2008-10-01
- First posted
- 2005-05-17
- Last updated
- 2014-08-06
Locations
320 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00111020. Inclusion in this directory is not an endorsement.